Screening for prostate cancer starting at age 50–54 years
نویسندگان
چکیده
منابع مشابه
PSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملA rationale for starting breast cancer screening under age 50.
Most countries which have implemented service screening on breast cancer invite women from age 50 [1]. With regard to younger women, findings from the UK age trial [2] showed the same trend as previous studies [3] that screening below age 50 has a positive effect on breast cancer mortality. For women screened at 40–49, Moss et al. [2] reported a breast cancer mortality reduction of 17% at 10-ye...
متن کاملScreening for prostate cancer among men 75 years of age or older.
The Washington Death with Dignity Act: 1. Initiative Measure 1000. (Accessed November 18, 2008, at http://wei.secstate.wa.gov/ osos/en/Documents/I1000-Text%20for%20 web.pdf.) Quill TE. Legal regulation of physician2. assisted death — the latest report cards. N Engl J Med 2007;356:1911-3. Ganzini L, Goy ER, Dobscha SK. Why Or3. egon patients request assisted death: family members’ views. J Gen I...
متن کاملScreening for prostate cancer.
In the United States, prostate cancer will affect 1 man in 6 during his lifetime. Since the mid-1980s, screening with the prostate-specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. A decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved t...
متن کاملScreening for prostate cancer.
Epidemiologically, screening is justified by the importance of the disease and the lack of prospects for primary prevention, but evidence from natural history is unhelpful since men are more likely to die with, rather than from, prostate cancer. The available screening tests do not always detect men whose lesions could result in future morbidity or mortality. Evidence is limited for the benefit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer Research and Therapeutics
سال: 2019
ISSN: 0973-1482
DOI: 10.4103/jcrt.jcrt_668_16